Aggressive portfolio rebalancing defined Duquesne Family Office LLC’s Q1 2026 activity. The firm expanded its $3.38 billion portfolio to 68 holdings, initiating 30 completely new positions. Natera (NTRA) commanded 18.1% of the portfolio; EWZ (8.7%), Insmed (INSM) (5.6%), TSM (5.0%), and RSP (4.7%) comprised its top five exposures.

Duquesne Family Office LLC made significant new purchases in Q1 2026, allocating $60.6 million to Broadcom Inc (AVGO). The semiconductor giant offers critical infrastructure components, positioning Duquesne for upside from data center expansion and artificial intelligence hardware demand. A $36.2 million investment went into Global X Fds (ARGT), signaling conviction in Argentina’s equity market recovery potential following recent political shifts. Caris Life Sciences Inc (CAI) also entered the portfolio with a $33.9 million allocation. This biotech acquisition points to Duquesne’s interest in precision oncology diagnostics and therapy selection advancements.

Duquesne’s Q1 activity reveals a collection of targeted bets across distinct growth vectors. Revolution Medicines Inc (RVMD) received a $30.7 million position, complementing the Caris investment with a direct play on oncology drug development. Sandisk Corp (SNDK) joined the portfolio with $24.2 million, a bet on specialized memory solutions. Humana Inc (HUM) secured a $23.8 million allocation, highlighting exposure to the evolving US healthcare payer market and demographic trends. These new positions, spanning enterprise technology, biotech innovation, emerging markets, and healthcare services, indicate a strategy of capitalizing on specific, high-conviction narratives rather than broad sector plays.

Duquesne Family Office LLC significantly increased its conviction in several existing holdings during Q1 2026. The institutional manager boosted its stake in YPF by a striking 433%, expanding the position to $149.6 million. This aggressive increase signals a potent belief in the Argentine energy company’s prospects. Duquesne also added 22% to its largest existing position, Natera (NTRA), growing it to $612.7 million.

Duquesne Family Office further deepened existing commitments, expanding its exposure to TBBB by 16%, bringing that holding to $110.0 million. The firm added 17% to Sea Ltd. (SE), increasing its value to $91.1 million. Alcoa (AA) also grew its presence, with a 9% add making the position worth $99.1 million. These targeted additions across varying sectors reveal a consistent strategy of reinforcing confidence in existing holdings rather than initiating new positions during the quarter.

Duquesne Family Office LLC, the investment manager, significantly curtailed several holdings during 2026’s first quarter. George Soros’s former protégé executed deep cuts in industrial and pharmaceutical names. Woodward Inc. saw a 64% reduction, significantly lowering its industrial sector footprint. Teva Pharmaceutical Industries Ltd. faced a 60% trim, indicating a sharp drop in conviction for the drugmaker. Ishares Inc. EWZ, the Brazil-focused exchange-traded fund, experienced a 51% reduction, signaling a retreat from specific emerging market exposure.

Duquesne also reduced its Invesco Exchange Traded Fd T RSP position by 30%, scaling back its equal-weight S&P 500 bet. Insmed Inc. saw a 22% decrease in shares. Taiwan Semiconductor Manufacturing Co. had a 9% cut, a smaller but still notable divestment from a semiconductor titan. These actions suggest a deliberate re-calibration of risk and sector allocation within the Duquesne portfolio.